Table 1.
Clinical and scan parameters for patients with and without DNA damage
| Total (n=57) | No DNA Damage (n=21) | DNA Damage (n=36) | p-value | |
|---|---|---|---|---|
| Clinical Parameters | ||||
| Age at enrollment, years | 67 (56–79) | 73 (63–77) | 66.5 (54–88) | 0.67 |
| Sex | 0.33 | |||
| Male (%) | 78.9 (45/57) | 71.4 (15/21) | 83.3 (30/36) | |
| Female (%) | 21.1 (12/57) | 28.6 (6/21) | 16.7 (6/36) | |
| BMI (kg/m2) | 26.5 (24.4 – 29.4) | 25.7 (24.2 – 30.1) | 27.1 (24.4 – 30.2) | 0.66 |
| Race | ||||
| White (%) | 80.7 (46/57) | 71.4 (15/21) | 86.1 (31/36) | 0.18 |
| Non-White (%) | 19.3 (11/57) | 28.6 (6/21) | 13.9 (5/36) | |
| Current smoking (%) | 21.1 (12/57) | 14.2 (3/21) | 25.0 (9/36) | 0.27 |
| History of cancer (%) | 22.8 (13/57) | 23.8 (5/21) | 22.2 (8/36) | 0.57 |
| Scan parameters* | ||||
| Mean DLP (mGy·cm) | 1511.0 (969.7 – 2589.1) | 1105.9 (568.3 – 1431) | 2137.0 (1293.0 – 2740.9) | <0.0001 |
| Mean total effective dose (mSv) | 36.9 (26.1 – 61.3) | 30.2 (17.0 – 45.1) | 49.2 (32.6 – 71.3) | 0.004* |
| Mean blood radiation dose (mSv) | 29.8 (18.8 – 48.8) | 23.2 (8.8 – 31.5) | 39.6 (23.6 – 53.8) | <0.0001* |
| Mean iodine content (g) | 38.6 (33.3 – 46.9) | 35.0 (25.9 – 37.8) | 41.4 (33.3 – 48) | 0.01 |
*
Scan parameters reflect only the cohort of patients that underwent biomarker testing for DNA damage (n=57) and does not reflect the entire cohort (n=67).